Funding profile · Neurostimulation devices

Volt Health

One accelerator check of $120,000 is the entire capital record. There is no Form D, no priced round on file, and no filing of any kind with the SEC under the company name.

$120KTotal capital on record, reported identically by PitchBook and Tracxn
$0Regulation D offerings filed with the SEC under the company name
$1.71MImplied post money if $120,000 bought 7 percent on the 2017 standard terms
2Deals recorded by PitchBook, Mar 2017 and Mar 2022

Data as of September 24, 2026. Company-reported figures are labeled.

Rounds at a glance

When Round Amount Investors Source
Sep 2014 No financing recorded None disclosed Entity listed as Volts Medical, Mountain View Prize listing
Mar 21, 2017 Accelerator, Y Combinator Winter 2017 $120,000 reported Y Combinator, recorded as one institutional investor PitchBook, Tracxn
2017 Listed by Tracxn as a Seed round $120K total, 1 round 1 investor Tracxn
Mar 1, 2022 Secondary transaction, private Not disclosed Not disclosed PitchBook
2014 to 2026 Federal grants None No NIH or NSF award NIH, NSF
2014 to 2026 Regulation D offerings None No Form D filer of this name SEC EDGAR

What the filings show

Nothing, because there are none. A search of SEC EDGAR returns no Form D filed by Volt Health, and no Regulation D notice by any related filer or single-company vehicle. The absence is not proof that no money moved. Companies that sell securities under Section 4(a)(2) rather than Regulation D file no Form D at all, and a lone accelerator safe frequently produces no notice. It does mean there is no filed document that names an officer, a director, an offering size or an investor count.

What exists instead is two commercial databases reporting the same number. PitchBook lists total raised of $120K across two recorded deals: an accelerator or incubator deal completed March 21, 2017, and a private secondary transaction completed March 1, 2022. Tracxn reports $120K in one round, a 2017 seed, with one investor and one institutional investor, and a last known valuation dated January 1, 2017.

Reading the filings

  1. The whole capital record is one standard accelerator check.Y Combinator’s published terms in early 2017 read: “We have a standard deal at YC: we’ll invest $120k in return for 7% of the company.” The $120,000 both databases report matches that figure exactly. Divide it out and the implied post money is $120,000 divided by 0.07, about $1.71 million. Tracxn dating its last known valuation to January 1, 2017 is consistent with that being the only valuation event on file.
  2. No Form D means no priced round was reported through the SEC.A Form D is due within 15 days of the first sale in a Regulation D offering. None exists. Either every dollar after the accelerator came in outside Regulation D, or no dollar came in. The two databases agreeing on $120,000 nine years later points to the second reading.
  3. The 2022 entry is a secondary, not a raise.PitchBook logs the March 1, 2022 event as a secondary transaction, private. In a secondary, an existing holder sells to another holder. No new capital enters the company and no proceeds reach its balance sheet. Counting it as funding would double count the same shares.
  4. The timing sits on top of the website going dark.The last Internet Archive capture of volthealth.com returning a normal page is dated January 28, 2022. The first capture returning 404 is dated March 15, 2022. The recorded secondary falls between the two, on March 1, 2022.
  5. Non-dilutive capital was available and was not taken.NIH and NSF both fund early neurostimulation work through SBIR. NIH RePORTER returns zero projects for the company. Peer companies in the same indication used that money: Elidah and Avation Medical both reached FDA clearance, and Avation registered a clinical study, NCT04547920, that appears on its 510(k) record.
  6. Tracxn ranks the company 117th of 139 in its own competitive set.The three it puts at the top, Axonics, Amber Therapeutics and Valencia Technologies, are reported at $143M, $116M and $56.9M raised. Against $120K, this is not a funding gap, it is a different category of company.

Commercial signals

Signal Detail Source type
Regulatory No FDA 510(k), PMA or De Novo, and no establishment registration, as of Sep 24, 2026. Not found
Clinical No study registered on ClinicalTrials.gov. Not found
Intellectual property No patent lists Volt Health as assignee. The founder’s 12 patent records all run through Aerin Medical. Not found
Product No named product, no price, no customers, no distribution agreement found. Not found
Web presence volthealth.com last returned a normal page on Jan 28, 2022 and has returned 404 since Mar 15, 2022. Public record
Status Tracxn classifies the company as deadpooled, with 1 to 10 employees as of July 2024. PitchBook still carries it as Private. The Y Combinator directory entry remains published. Data providers

What to watch

  • A first Form D. It would be the earliest SEC evidence of any priced round and would name officers, directors and an investor count.
  • A 510(k) under product code QAJ or NAM, the two FDA classes for non-implanted urinary incontinence stimulators.
  • A patent application naming Volt Health as assignee. Applications publish about 18 months after filing.
  • Any revision to the Y Combinator directory entry, which still carries the March 2017 pitch.

The Volt Health story on Healthcare DiscoveryHealthcare Discovery

Related companies

  • UroDev Medical: Also in Medical Devices. A Minnesota company built around a fully internal, remote controlled urinary catheter for men with chronic urinary retention
  • Actipulse Neuroscience: Also in Medical Devices. A Mexico-rooted company selling a clinician-operated magnetic stimulation console across Latin America
  • Corveus Medical: Also in Medical Devices. A Houston company building a catheter that deactivates one sympathetic nerve to relieve congestion in heart failure
  • Allotrope Medical: Also in Medical Devices. A Houston surgical resident built a box that makes the ureter move on command, cleared it in 2020, and sold the company in 2023

Sources

  1. Public recordSEC EDGAR company and full-text search for Volt Health, no filingsSEC · Sep 24, 2026
  2. Public recordNIH RePORTER project search, organisation Volt Health, zero resultsNIH · Sep 24, 2026
  3. Public recordFDA 510(k) and De Novo databases, no record for Volt HealthFDA · Sep 24, 2026
  4. Public record510(k) K220454, Vivally System, Avation Medical, listing study NCT04547920FDA · Apr 3, 2023
  5. Public recordWayback Machine capture index for volthealth.comInternet Archive · queried Sep 24, 2026
  6. Public recordPatent assignee search for Volt Health, no resultsJustia Patents · Sep 24, 2026
  7. Data providerVolt Health company profile, funding and deal historyPitchBook · accessed Sep 24, 2026
  8. Data providerVolt Health company profile, funding, status and competitor rankingTracxn · accessed Sep 24, 2026
  9. IndependentAll 51 startups that debuted at Y Combinator W17 Demo Day 2TechCrunch · Mar 21, 2017
  10. CompanyThe YC Deal, archived terms pageY Combinator, Internet Archive · Mar 2017
  11. CompanyVolt Health directory entry and founder biographyY Combinator · accessed Sep 24, 2026

Compiled from SEC, FDA, NIH and Internet Archive public records and published reports as of September 24, 2026. Form D notices report offerings under Regulation D; the absence of one does not by itself establish that no securities were sold. Healthcare Venture Capital Fund holds no position in Volt Health. This page is not an offer to sell or a recommendation to buy any security.